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Seeking a uniﬁed theory of achieving
the state induced by anesthetics is deep
in the biophysicist’s psyche. A search
of the Biophysical Journal contents for
titles containing ‘‘anesthetic’’ yields 84
hits. Both sleep and anesthesia uncou-
ple functional connections between
activities in hemispheres of the brain,
as demonstrated in functional magnetic
resonance imaging (1). At the molecu-
lar level, however, it appears that
different anesthetics have varied tar-
gets, and instead of a uniﬁed theory of
action, there is a complicated puzzle.
Speciﬁc interactions between neuro-
transmitter-gated channels and anes-
thetics receive much attention. Many
volatile (and also some intravenous)
anesthetics modulate GABAA recep-
tors. However, the group of inhaled
anesthetics—xenon, nitrous oxide, and
cyclopropane—mainly inﬂuence the
function of postsynaptic glutamate
NMDA receptors instead (reviewed in
Sanders et al. (2)). At intermediate
doses, these inhalant anesthetics lead to
analgesia and euphoria and, at higher
doses, to deep, surgical anesthesia.
An article by Colloc’h et al., in this
issue, places one more piece of the puz-
zle by reporting the ﬁrst observation of
nitrous oxide (N2O) bound in x-ray
structures of proteins relevant to possi-
ble cellular targets (3). This study com-
pares nitrous oxide and xenon binding
in a putative model of the NMDA
receptor and in a globular protein. One
site in each protein is available to either
gas, whereas a second molecule of
nitrous oxide also binds to each protein.
Since the relative anesthetic potencies
of these gases have been determined
previously, structural results and func-
tion can be compared. AnnexinV has
properties of ligand (calcium) gating
that make it a reasonable model of the
extracellular part of NMDA receptor
function, whereas urate oxidase is
taken to represent intracellular proteins
with large hydrophobic cavities. The
annexinV structure was solved in the
presence of calcium. In this state, a
tryptophan side chain is displaced away
from the core of the structure, leaving
the cavity to which both gases bind.
The interaction of xenon with protein
cavities can be examined experimen-
tally by methods of x-ray diffraction,
illustrated in Colloc’h et al. (3) and
reference 27 in that article and by NMR
(4). The nature of xenon-cavity inter-
actions can be approached with two
types of NMR experiment. NMR chem-
ical shifts (1H-15N correlation spectros-
copy) of side chains lining protein
cavities titrate with xenon overpressure,
and the 129Xe chemical shifts titrate
at constant xenon pressure with varia-
tion in protein concentration (4). In
either case, xenon binds to known
protein cavities with weak afﬁnities
of ;10–200 M21 ((4) and references
therein). The volumes of some, but not
all, cavities expand when xenon is
bound (3), and xenon is able to displace
other small ligands from cavities (4).
Colloc’h et al. ﬁnd that xenon binding
expands the annexinV cavity left vacant
by Trp displacement, and likewise the
other cavities studied. They suggest that
binding of anesthetics of the xenon/
nitrous oxide class, by expanding cav-
ity volume, may reduce some feature of
protein ﬂexibility that is necessary for
function. This general concept is a good
basis for design of future experiments,
but most puzzling is how it can lead to
speciﬁcity for a particular neurotrans-
mitter target.
One place to look for the next piece
in the puzzle is the membrane portion
of neurotransmitter receptors. Recent
studies of channels that transport gas
molecules may point the way. The Rh
factors of human red blood cells are
thought to facilitate entry of carbon
dioxide gas and these membrane pro-
teins are structurally related to the am-
monia family of transporters (the Amts)
(5). The x-ray structure of one Amt in
fact reveals 15 sites per monomer for
xenon binding (6). A site occupied by
two of the xenon atoms is a large,
hydrophobic cavity on the cytoplasmic
side of Amt-1. It is suggested that this
cavity in the Amt may be required for
conformational changes related to func-
tion (6), and in that sense, arguments
could be advanced that cavity expan-
sion by xenon occupation might in-
hibit Amt-1 function, as is argued for
annexinV (3). Even more intriguing is
that three strong xenon sites are found
in the Amt-1 transport channel, and
there are others between monomers
in the trimer. From other examples,
xenon binding is not limited to hydro-
phobic sites. It seems possible then that
the effect of xenon and other anes-
thetics on neurotransmitters might in-
volve the channel itself. This returns the
discussion to the original study impli-
cating NMDA receptors as the target
of xenon anesthesia. Xenon inhibits
by 60% the maximum inward current
through NMDA receptors in cultured
neurons (reference 9 in Colloc’h et al.
(3)) but does not compete with NMDA.
Conformational ﬂexibility in the lig-
and-binding core of NMDA receptors
is understood at the structural level (7).
Revealing xenon/nitrous oxide sites
in both the ligand-binding portion and
the channel itself could bring us closer
to a general theory of inhaled anes-
thetic action and to a general state of
euphoria.
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